1 **Category: Infectious Disease**

2

3 **TITLE:**

4 **EVALUATION OF THE ABBOTT SARS-COV-2 IG-G ASSAY.**

5

6 **Authors:**

7 Lau CS¹, Hoo SP¹, Liang YL¹, Aw TC^{1,2,3*}

8 1. Department of Laboratory Medicine, Changi General Hospital, Singapore.

9 2. Department of Medicine, National University of Singapore, Singapore.

10 3. Academic Pathology Program, Duke-NUS Medical School, Singapore.

11

12 * Corresponding Author

13 **Address:** Department of Laboratory Medicine, CHANGI GENERAL

14 HOSPITAL, 2 SIMEI STREET 3, SINGAPORE 529889

15 **E-mail:** tarchoon@gmail.com

16 **Phone:** +65 – 68504927

17 **Fax:** +65 – 64269507

18

19 **Disclosure:** All authors have nothing to disclose.

20

21 **ABBREVIATIONS**

22 SARS-CoV-2 – Novel severe acute respiratory syndrome coronavirus 2

23 COVID-19 – Coronavirus disease 2019

24 CDC – Centers for Disease Control and Prevention

25 RCPA – Royal College of Pathologists of Australasia

26 RF – Rheumatoid factor

27 PCR – Polymerase chain reaction

28 COI – Cut-off index

29 CV – Inter-assay precision

30 CAP – College of American Pathologists

31 PPA – Positive percentage agreement

32 POS – Post positive PCR

33 NPA – Negative percentage agreement

34 FDA – Food and Drug Administration

35

36

37

38

39

40

41

42 ABSTRACT

43 **Introduction:** Antibodies to the novel severe acute respiratory syndrome coronavirus 2
44 (SARS-CoV-2) can increase as soon as 10-13 days after infection. We describe our
45 evaluation of the Abbott SARS-CoV-2 IgG assay on the Architect immunoassay analyser.

46

47 **Methods:** We assessed the precision, sensitivity, and specificity of the Abbott SARS-CoV-2
48 IgG assay in samples from polymerase chain reaction (PCR) positive patients and healthy
49 healthcare workers. The manufacturer cut-off index (COI) of 1.4 was adopted to identify
50 positive results. We examined the assay cross-reactivity with other viral antibodies
51 (influenza/dengue/hepatitis C/hepatitis B) and rheumatoid factor (RF). The sample
52 throughput of the Abbott assay was also assessed.

53

54 **Results:** The Abbott assay showed excellent precision, with a CV of 3.4% for the negative
55 control (COI = 0.06) and 1.6% for a high positive serum sample (COI = 8.6). Residual serum
56 was available from 57 inpatients not initially suspected of having COVID-19, 29 of whom
57 tested positive for SARS-CoV-2 IgG. The Abbott assay has a sensitivity of 90.9-100% when
58 tested in 54 subjects ≥ 14 days post PCR positive, and a specificity of 100% (N = 358). There
59 was no cross-reactivity with other viral antibodies (influenza/dengue/hepatitis C/hepatitis B)
60 and RF. The Architect Abbott assay has a throughput of 100 samples in 70 minutes.

61

62 **Conclusion:** The Abbott SARS-CoV-2 IgG assay shows excellent performance that is well
63 within FDA and CDC guidelines when testing patients ≥ 14 days POS with little cross-
64 reactivity from other viral antibodies. There is some evidence that SARS-CoV-2 IgG
65 develops early in the disease process.

66

67 **IMPACT STATEMENT**

68 With the current SARS-CoV-2 pandemic still ongoing, laboratories are hard pressed to
 69 introduce SARS-CoV-2 antibody testing to help as an indirect marker for infection to identify
 70 patients with prior infection/exposure. The Abbott SARS-CoV-2 IgG assay has excellent
 71 performance with good precision, specificity, and sensitivity ≥ 14 days after a positive SARS-
 72 CoV-2 PCR test, with a competitive throughput of 100 samples in 70 minutes. It shows no
 73 cross-reactivity with other viral antibodies (influenza/dengue/hepatitis B/hepatitis C) and
 74 rheumatoid factor. We have also found evidence of early antibody development in some
 75 patients before they tested positive on the SARS-CoV-2 PCR test.

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90 INTRODUCTION

91 The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to mild
 92 or moderate coronavirus disease 2019 (COVID-19) with cough, fever, malaise, myalgias,
 93 gastrointestinal symptoms and anosmia (1), or a severe disease with acute respiratory
 94 distress syndrome (2). The need for the serological diagnosis of SARS-CoV-2 has become
 95 acute. The Centers for Disease Control and Prevention (CDC) (3) and the Royal College of
 96 Pathologists of Australasia (RCPA) (4) stipulate that only viral testing (nucleic acid or
 97 antigen) is the standard test to diagnose acute infection. However, some studies (5, 6) show
 98 that the SARS-CoV-2 antibodies can increase as soon as 10-13 days after infection.
 99 Antibody tests can act as an indirect marker for infection and help identify patients with prior
 100 infection/exposure who have developed an immune response (7). Abbott has developed a
 101 SARS-CoV-2 IgG assay for use with its Architect immunoassay analysers for the rapid
 102 testing of large numbers of samples. We describe our evaluation of the Abbott SARS-CoV-2
 103 IgG assay.

104

105 MATERIALS AND METHODS

106 Patient cohorts:

107 Residual serum from cases with suspected or confirmed SARS-CoV-2 infection from April to
 108 May 2020 were recruited. Samples testing positive for dengue fever/Anti-HCV/HBsAg/anti-
 109 HBc IgM and rheumatoid factor (RF) were used to check for cross-reactivity in the SARS-
 110 CoV-2 IgG assay. Volunteers (laboratory staff and frontline healthcare workers) from our
 111 hospital also provided serum samples as control subjects. All samples were collected in
 112 plain serum tubes.

113 Instrumentation and analysis:

For SARS-CoV-2 polymerase chain reaction (PCR) testing, our hospital molecular laboratory employs a duplex real-time PCR that targets the N and E genes using a Qiagen EZ1 extraction system and Rotor Gene Q amplification system. The Abbott SARS-CoV-2 IgG assay is a qualitative chemiluminescent microparticle immunoassay used for the detection of IgG antibodies to SARS-CoV-2 (undisclosed epitope on the viral nucleocapsid) in human serum/plasma on the ARCHITECT i2000 System. The sample, SARS-CoV-2 antigen coated paramagnetic microparticles, and assay diluent are combined and incubated. Thereafter, anti-human IgG acridinium-labelled conjugate is added to create a reaction mixture. Following the addition of pre-trigger and trigger solutions, the resulting chemiluminescent reaction is directly proportional to the amount of IgG antibodies. When compared to the mean chemiluminescent signal of a calibrator, an IgG index is derived with a reported cut-off index (COI) of 1.4. The assay has a stated inter-assay precision (CV) of 5.9% and 1.2% for negative and positive controls at a mean COI of 0.04 and 3.53. The reported assay specificity is 99.6% and sensitivity of 100% for samples ≥ 14 days post symptom onset. To prevent potential interactions, maintenance has to be performed to and following the batching of 50 SARS-CoV-2 IgG samples (Abbott SARS-CoV-2 IgG assay package insert, H07891R02, April 2020).

Statistical analyses were performed using MedCalc software v19.3.1 (MedCalc, Ostend, Belgium). As this work was part of routine evaluation of new diagnostic assays, it was deemed exempt by our institutional review board.

RESULTS

For precision analysis, 5 pools (including negative and positive Abbott controls, and 3 positive serum samples over a range of COI values) were run 5 times daily over 5 days as per the CLSI EP15-A3 protocol (8). The Abbott assay showed excellent precision, with a CV

of 3.4% (negative control, COI = 0.06) and 1.6% (serum sample, COI = 8.6) (Supplemental Table 1).

For sensitivity testing [positive percentage agreement, (PPA)], we used 338 PCR positive COVID-19 cases; cases with unknown PCR status (N = 5) and PCR negative cases (N = 10) were excluded. 57 of these cases were residual samples from inpatients who were not initially suspected of having COVID-19 but subsequently tested positive for SARS-CoV-2 PCR. Notably, 29 of these 57 samples were positive for IgG prior to having a positive PCR test. Of the remaining 266 samples, the PPA increased to 90.9% after 14 days post positive PCR (POS) and 100% by 21 days POS (see Table 1).

< TABLE 1 >

For specificity testing [negative percentage agreement (NPA)], we included 294 samples from healthcare workers, 46 samples positive for dengue, 3 samples positive for Anti-HCV, 8 samples positive for HBsAg, 2 samples positive for anti-HBc IgM, and 5 RF positive samples. All these samples were from subjects with no suspicion for COVID-19. None of these cases tested positive, yielding a total specificity of 100% (95% CI 98.98 to 100.00) (See Table 2). The sero-negativity of our healthcare workers also underscores the adequacy of our personal protective equipment measures. However, they remain at risk for future COVID-19 infections, and continued safety precautions should still be enforced. We also analysed for any potential cross-reactivity from antibodies consequent to recent influenza vaccination (239 staff had received their influenza vaccination 4 weeks prior to testing). None of these cases (dengue, recent influenza vaccination cases, or positive Anti-HCV, HBsAg, anti-HBc IgM and RF) tested positive for SARS-CoV-2 IgG.

<TABLE 2>

165

166 The throughput of the Architect Abbott assay was examined. The Architect was able to
167 analyse 100 specimens for SARS-CoV-2 IgG in 1 hour 9 minutes and took 2 hours 9
168 minutes to analyse 250 specimens.

169

170 **DISCUSSION**

171 The Abbott SARS-CoV-2 IgG assay shows excellent performance, with a CV of 3.4% and
172 1.9% for the negative and positive calibrators. The diagnostic sensitivity of this assay is 90.9-
173 100% ≥ 14 days POS, with a specificity of 100%. This is in close agreement with the
174 manufacturer's specifications. Our results are also in keeping with other studies (9-12) that
175 have evaluated the Abbott SARS-CoV-2 IgG assay, where the sensitivity/PPA increases to
176 $>90\%$ after 14 days post symptom onset. The US CDC and the Food and Drug
177 Administration (FDA) have stipulated a sensitivity of 90% and specificity of 95% for an
178 acceptable SARS-CoV-2 serology test (13, 14). The Abbott assay easily falls within these
179 requirements. Furthermore, the Abbott assay has an acceptable throughput, which is
180 comparable to other SARS-CoV-2 immunoassays. In the latest revision of the package insert
181 (Abbott SARS-CoV-2 IgG package insert, H70891R03, May 2020), it is heartening to note
182 that the requirement for batch analysis and maintenance pre- and post-testing has been
183 removed.

184 In our study we have used days POS to categorize our population. Using the onset of patient
185 symptoms as a criterion for SARS-CoV-2 classification will result in the exclusion of
186 asymptomatic patients (15, 16). Using days POS mitigates against this pitfall. We also found
187 29 patient samples that tested positive for SARS-CoV-2 IgG before a positive PCR test. This
188 underscores the fact that SARS-CoV-2 antibody development may occur earlier than
189 expected in some cases. Our study also confirms that the assay remains specific even in
190 patients with previous dengue infection, recent influenza vaccination, or in the presence of

Anti-HCV, HBsAg, anti-HBc IgM and RF. A recent report (17) found that SARS-CoV-2 infection may cause false-positive dengue antibody results. It is noteworthy that positive dengue serology in 46 patients did not cause a false positive SARS-CoV-2 IgG. Other evaluations of the Abbott assay also demonstrate little cross-reactivity in patients with previous viral infections and haemodialysis (9). Finally, we have also provided data on the sample throughput of the Abbott assay. A limitation of our study is that it is a single centre study, and we do not have the sero-prevalence of SARS-CoV-2 in our community population. In addition, we only had few samples for cases before and after 0-<7 days POS. Further studies on larger populations would be desirable.

Conclusion

Overall, our results show that the Abbott SARS-CoV-2 IgG assay has excellent performance and is highly comparable both with the manufacturer's information and other published studies. We look forward to larger studies over longer periods of time to further evaluate the use of serological assays in the management of COVID-19.

References

- (1) Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. [Epub ahead of print] N Engl J Med 24 April, 2020 as Doi: 10.1056/NEJMcp2009249.
- (2) Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. [Epub ahead of print] N Engl J Med 15 May, 2020 as Doi: 10.1056/NEJMcp2009575.
- (3) Centers for Disease Control and Prevention. Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html>. (2020, Accessed 22 May 2020).
- (4) The Royal College of Pathologists of Australia. Position Statement, COVID19 IgG/IgM Rapid POCT Tests. <https://www.rcpa.edu.au/getattachment/bf9c7996-6467-44e6-81f2->

- 218 e2e0cd71a4c7/COVID19-IgG-IgM-RAPID-POCT-TESTS.aspx. (2020, Accessed 22 May
219 2020).
- 220 (5) Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and Spike
221 Protein-based ELISAs for 2 detecting antibodies against SARS-CoV2. [Epub ahead of
222 print] J Clin Microbiol 30 March, 2020 as Doi: 10.1128/JCM.00461-20.
- 223 (6) Long Q, Deng J, Chen J, Hu J, Liu B, Liao P, Lin Y, et al. Antibody responses to SARS-
224 CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical
225 practice. [Preprint] medRxiv 20 March, 2020 as Doi:
226 <https://doi.org/10.1101/2020.03.18.20038018>.
- 227 (7) U.S. Food and Drug Administration. Important Information on the Use of Serological
228 (Antibody) Tests for COVID-19 - Letter to Health Care Providers.
229 [https://www.fda.gov/medical-devices/letters-health-care-providers/important-information-](https://www.fda.gov/medical-devices/letters-health-care-providers/important-information-use-serological-antibody-tests-covid-19-letter-health-care-providers)
230 [use-serological-antibody-tests-covid-19-letter-health-care-providers](https://www.fda.gov/medical-devices/letters-health-care-providers/important-information-use-serological-antibody-tests-covid-19-letter-health-care-providers). (2020, Accessed 22
231 May 2020).
- 232 (8) Clinical and Laboratory Standard Institute (CLSI). User Verification of Precision and
233 Estimation of Bias; Approved Guideline-Third Edition, CLSI document EP15-A3. PA
234 Wayne PA:CLSI 2014.
- 235 (9) Public Health England. Evaluation of the Abbott SARS-CoV-2 IgG for the detection of
236 anti-SARSCoV-2 antibodies.
237 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887221/PHE_Evaluation_of_Abbott_SARS_CoV_2_IgG.pdf)
238 [_data/file/887221/PHE Evaluation of Abbott SARS CoV 2 IgG.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887221/PHE_Evaluation_of_Abbott_SARS_CoV_2_IgG.pdf). (2020, Accessed
239 26 May 2020).
- 240 (10) Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al.
241 Clinical Performance of Two SARS-CoV-2 Serologic Assays. [Epub ahead of print] Clin
242 Chem 13 May, 2020 as Doi: 10.1093/clinchem/hvaa120.
- 243 (11) Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-
244 CoV-2 in Patients of Novel Coronavirus Disease 2019. [Epub ahead of print] Clin Infect
245 Dis 28 March, 2020 as Doi: 10.1093/cid/ciaa344.

- (12) Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance Characteristics of the Abbott Architect 1 SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. [Epub ahead of print] J Clin Microbiol 7 May, 2020 as Doi: 10.1128/JCM.00941-20.
- (13) Centers for Disease Control and Prevention. Interim Guidelines for COVID-19 Antibody Testing. <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html> (2020, accessed 8 June 2020).
- (14) US Food and Drug Administration. EUA Authorized Serology Test Performance. <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance> (2020, accessed 29 May 2020).
- (15) Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. [Epub ahead of print] Euro Surveill 12 March, 2020 as Doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
- (16) Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 411–5.
- (17) Yan G, Lee CK, Lam L, Yan B, Chua YX, Lim A, et al. Covert COVID-19 and false-positive dengue serology in Singapore. [Epub ahead of print] Lancet 4 March, 2020 as Doi: [https://doi.org/10.1016/S1473-3099\(20\)30158-4](https://doi.org/10.1016/S1473-3099(20)30158-4).

Table 1: Abbott assay sensitivity (positive percentage agreement) by days post positive PCR.

Days POS	N	IgG positive	IgG negative	PPA (%)	95% CI
0-<7	155	76	79	49.03	40.93 to 57.18
7-<14	57	43	14	75.44	62.24 to 85.87
14-<21	22	20	2	90.91	70.84 to 98.88
≥21	32	32	0	100.00	89.11 to 100.00

Table 2: Abbott assay interference analysis and specificity (negative percentage agreement).

	N	Abbott negative	Abbott positive
Healthcare workers	294	294	0
Dengue fever	46	46	0
Anti-HCV	3	3	0
HBsAg	8	8	0
Anti-HBc IgM	2	2	0
RF positive	5	5	0
Total	358	358	0
Abbott NPA	100% (95% CI 98.98 to 100.00)		